论文部分内容阅读
本文研究了HAART中联合与不联合使用羟基脲,经5次固定间隙疗法(structured treatment interruption, STI)后,对血浆病毒载量检测点变化、HIV-1特异性应答的作用。研究对象为一组慢性HIV感染、病毒载量<20拷贝/mL并接受HAART者,他们被随机进行持续的HAART和HAART+羟基脲(HU)治疗达24周,此后有5次STI。HU在1～3次的STI中也停用,但在4～8次STI中继续使用。对第5次STI期间,VL检测点持续<5000拷贝/mL患者人数进行统计。结果在5次STI后平均随访48周,HU组9例中有8例、HAART组10例中有4例在这一基线。5次STI后,患者的中和活性、从基线计数的总CTL和淋巴增殖细胞(LRP)
This study investigated the effect of hydroxyurea with or without hydroxyurea on the detection of changes in plasma viral load and the HIV-1-specific response to HAART with 5-fold structured treatment interruption (STI). The study population consisted of a group of chronic HIV infections with a viral load of <20 copies / mL and received HAART who were treated with continuous HAART and HAART + hydroxyurea (HU) for 24 weeks followed by 5 STIs thereafter. HU was also discontinued in 1 to 3 STIs but continued to be used in 4 to 8 STIs. During the fifth STI, statistics of the number of patients with <5000 copies / mL sustained at the VL test point were counted. RESULTS: After a mean follow-up of 48 weeks after 5 STIs, 8 of 9 patients in the HU group and 4 of 10 patients in the HAART group were at this baseline. After 5 STIs, the patient’s neutralizing activity, total CTL and lymphocyte proliferation (LRP) counts from baseline,